Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPA-501-ALLO for COVID-19-Related ARDS
NCT04482699Phase 2Terminated
- Sponsor
- Rapa Therapeutics
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RAPA-501-Allo in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (4 arms), sponsored by Rapa Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 7 days and 30-day Mortality Rate. Started Dec 2020; status: terminated.
02
Drugs
RAPA-501-Allo
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04482699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482699.